BR112023013898A2 - Heterodímero compreendendo dois polipeptídeos selecionados a partir do grupo que consiste em proteína reguladora de sinal alfa, morte programada 1, imunorreceptor de células t com domínios da imunoglobulina e do motivo de inibição baseado em tirosina de imunorreceptor, receptor de leucócitos tipo imunoglobulina, sub família b, membro 2, e lectina 10 semelhante à imunoglobulina de ligação ao ácido siálico, composição compreendendo o heterodímero, construção ou sistema de ácido nucleico, célula hospedeira, e, métodos para produzir um heterodímero, para tratar uma doença e para ativar células imunes - Google Patents

Heterodímero compreendendo dois polipeptídeos selecionados a partir do grupo que consiste em proteína reguladora de sinal alfa, morte programada 1, imunorreceptor de células t com domínios da imunoglobulina e do motivo de inibição baseado em tirosina de imunorreceptor, receptor de leucócitos tipo imunoglobulina, sub família b, membro 2, e lectina 10 semelhante à imunoglobulina de ligação ao ácido siálico, composição compreendendo o heterodímero, construção ou sistema de ácido nucleico, célula hospedeira, e, métodos para produzir um heterodímero, para tratar uma doença e para ativar células imunes

Info

Publication number
BR112023013898A2
BR112023013898A2 BR112023013898A BR112023013898A BR112023013898A2 BR 112023013898 A2 BR112023013898 A2 BR 112023013898A2 BR 112023013898 A BR112023013898 A BR 112023013898A BR 112023013898 A BR112023013898 A BR 112023013898A BR 112023013898 A2 BR112023013898 A2 BR 112023013898A2
Authority
BR
Brazil
Prior art keywords
heterodimer
immunoglobulin
cell
nucleic acid
methods
Prior art date
Application number
BR112023013898A
Other languages
English (en)
Portuguese (pt)
Inventor
Ami Tamir
Edwin Bremer
L Tykocinski Mark
Original Assignee
Kahr Medical Ltd
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Kahr Medical Ltd, Univ Jefferson filed Critical Kahr Medical Ltd
Publication of BR112023013898A2 publication Critical patent/BR112023013898A2/pt

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4702Regulators; Modulating activity
    • C07K14/4703Inhibitors; Suppressors
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503Immunoglobulin superfamily
    • C07K14/70521CD28, CD152
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70596Molecules with a "CD"-designation not provided for elsewhere
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2319/00Fusion polypeptide
    • C07K2319/30Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Zoology (AREA)
  • Molecular Biology (AREA)
  • Toxicology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Cell Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BR112023013898A 2021-01-13 2022-01-13 Heterodímero compreendendo dois polipeptídeos selecionados a partir do grupo que consiste em proteína reguladora de sinal alfa, morte programada 1, imunorreceptor de células t com domínios da imunoglobulina e do motivo de inibição baseado em tirosina de imunorreceptor, receptor de leucócitos tipo imunoglobulina, sub família b, membro 2, e lectina 10 semelhante à imunoglobulina de ligação ao ácido siálico, composição compreendendo o heterodímero, construção ou sistema de ácido nucleico, célula hospedeira, e, métodos para produzir um heterodímero, para tratar uma doença e para ativar células imunes BR112023013898A2 (pt)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163136687P 2021-01-13 2021-01-13
US202163139331P 2021-01-20 2021-01-20
PCT/IL2022/050055 WO2022153307A1 (en) 2021-01-13 2022-01-13 Type i membrane proteins heterodimers and methods of use thereof

Publications (1)

Publication Number Publication Date
BR112023013898A2 true BR112023013898A2 (pt) 2023-10-31

Family

ID=82447997

Family Applications (1)

Application Number Title Priority Date Filing Date
BR112023013898A BR112023013898A2 (pt) 2021-01-13 2022-01-13 Heterodímero compreendendo dois polipeptídeos selecionados a partir do grupo que consiste em proteína reguladora de sinal alfa, morte programada 1, imunorreceptor de células t com domínios da imunoglobulina e do motivo de inibição baseado em tirosina de imunorreceptor, receptor de leucócitos tipo imunoglobulina, sub família b, membro 2, e lectina 10 semelhante à imunoglobulina de ligação ao ácido siálico, composição compreendendo o heterodímero, construção ou sistema de ácido nucleico, célula hospedeira, e, métodos para produzir um heterodímero, para tratar uma doença e para ativar células imunes

Country Status (10)

Country Link
US (1) US20240076346A1 (https=)
EP (1) EP4277923A4 (https=)
JP (1) JP2024503685A (https=)
KR (1) KR20230169933A (https=)
AU (1) AU2022208466A1 (https=)
BR (1) BR112023013898A2 (https=)
CA (1) CA3204707A1 (https=)
IL (1) IL304381A (https=)
MX (1) MX2023008351A (https=)
WO (1) WO2022153307A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2769769C2 (ru) 2017-01-05 2022-04-05 Кахр Медикал Лтд. СЛИТЫЙ БЕЛОК SIRPα-4-1BBL И СПОСОБЫ ЕГО ПРИМЕНЕНИЯ
CN110536693B (zh) 2017-01-05 2023-12-22 卡尔医学有限公司 Pd1-41bbl融合蛋白及使用其的方法
US11566060B2 (en) 2017-01-05 2023-01-31 Kahr Medical Ltd. PD1-CD70 fusion protein and methods of use thereof
EP3820887A4 (en) 2018-07-11 2022-04-20 KAHR Medical Ltd. Pd1-4-1bbl variant fusion protein and methods of use thereof
KR102945860B1 (ko) 2018-07-11 2026-03-31 카 메디컬 리미티드 SIRPalpha-4-1BBL 변이체 융합 단백질 및 이의 사용 방법
CN111454369A (zh) * 2020-04-10 2020-07-28 润方(长春)生物科技有限公司 一种用于制备异二聚物蛋白质的方法
US20250051410A1 (en) * 2021-12-23 2025-02-13 Kahr Medical Ltd. Lilrb polypeptides and uses thereof

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5731168A (en) * 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
WO2014164519A1 (en) * 2013-03-12 2014-10-09 The Board Of Trustees Of The Leland Stanford Junior University Methods and compositions for inhibiting the effects of amyloid beta oligomers
WO2016023001A1 (en) * 2014-08-08 2016-02-11 The Board Of Trustees Of The Leland Stanford Junior University Multispecific high affinity pd-1 agents and methods of use
CN113831417B (zh) * 2017-05-08 2024-10-01 上海津曼特生物科技有限公司 双特异性重组蛋白及其应用
CN107857819A (zh) * 2017-07-03 2018-03-30 江苏西迪尔生物技术有限公司 多功能融合蛋白及其应用
EP3908664A4 (en) * 2019-01-07 2023-01-25 Thomas Jefferson University MULTIFUNCTIONAL FUSION PROTEINS AND THEIR USES
EP3947460A4 (en) * 2019-03-26 2023-05-10 Forty Seven, Inc. MULTISPECIFIC AGENTS FOR TREATMENT OF CANCER
TWI760751B (zh) * 2019-05-29 2022-04-11 美商美國禮來大藥廠 Tigit及pd-1/tigit-結合分子
CN110128550B (zh) * 2019-05-30 2023-01-13 南京惟亚德生物医药有限公司 一种新型的同时阻断免疫检查点pd-l1和tigit的复制型溶瘤腺病毒和应用
US20220267409A1 (en) * 2019-07-11 2022-08-25 Kahr Medical Ltd. Heterodimers and methods of use thereof

Also Published As

Publication number Publication date
IL304381A (en) 2023-09-01
MX2023008351A (es) 2023-10-10
KR20230169933A (ko) 2023-12-18
WO2022153307A1 (en) 2022-07-21
AU2022208466A1 (en) 2023-08-17
JP2024503685A (ja) 2024-01-26
AU2022208466A9 (en) 2024-07-11
CA3204707A1 (en) 2022-07-21
EP4277923A1 (en) 2023-11-22
US20240076346A1 (en) 2024-03-07
EP4277923A4 (en) 2025-01-22

Similar Documents

Publication Publication Date Title
BR112023013898A2 (pt) Heterodímero compreendendo dois polipeptídeos selecionados a partir do grupo que consiste em proteína reguladora de sinal alfa, morte programada 1, imunorreceptor de células t com domínios da imunoglobulina e do motivo de inibição baseado em tirosina de imunorreceptor, receptor de leucócitos tipo imunoglobulina, sub família b, membro 2, e lectina 10 semelhante à imunoglobulina de ligação ao ácido siálico, composição compreendendo o heterodímero, construção ou sistema de ácido nucleico, célula hospedeira, e, métodos para produzir um heterodímero, para tratar uma doença e para ativar células imunes
BR112022000319A2 (pt) Heterodímeros e métodos de uso dos mesmos
Inanobe et al. Gβγ directly binds to the carboxyl terminus of the G protein-gated muscarinic K+ channel, GIRK1
CN111836638B (zh) 针对突变的ras的hla i类限制性t细胞受体
Lanier Natural killer cell receptor signaling
Bryant et al. Mice, men and the relatives: cross-species studies underpin innate immunity
Hartleben et al. Neph-Nephrin proteins bind the Par3-Par6-atypical protein kinase C (aPKC) complex to regulate podocyte cell polarity
Gounari et al. Amino‐terminal domain of NF1 binds to DNA as a dimer and activates adenovirus DNA replication.
Sellers et al. Changing Fos oncoprotein to a Jun-independent DNA-binding protein with GCN4 dimerization specificity by swapping" leucine zippers"
McCormick et al. SV40 T antigen binds specifically to a cellular 53 K protein in vitro
Li et al. Cloning and characterization of Siglec-10, a novel sialic acid binding member of the Ig superfamily, from human dendritic cells
Xu et al. Two novel C-type lectins with a low-density lipoprotein receptor class A domain have antiviral function in the shrimp Marsupenaeus japonicus
Mallya et al. Characterization of the five novel Ly‐6 superfamily members encoded in the MHC, and detection of cells expressing their potential ligands
Latchman Transcription factors: a practical approach
Sever et al. Expression of tapasin in rainbow trout tissues and cell lines and up regulation in a monocyte/macrophage cell line (RTS11) by a viral mimic and viral infection
Moon et al. Tissue-specific expression of distinct spectrin and ankyrin transcripts in erythroid and nonerythroid cells.
KR20220143875A (ko) G12v 돌연변이를 갖는 ras에 대한 hla 클래스 i-제한된 t 세포 수용체
Ying et al. Cloning and characterization of rat Luman/CREB3, a transcription factor highly expressed in nervous system tissue
Shimada et al. Regulation of TFF3 expression by homeodomain protein CDX2
Mißbach et al. Alternative splicing after gene duplication drives CEACAM1-paralog diversification in the horse
McCarthy et al. Activin-A binds to a heterotrimeric receptor complex on the vascular endothelial cell surface. Evidence for a type 3 activin receptor.
Rahman et al. Interaction of human TNF and β2-microglobulin with Tanapox virus-encoded TNF inhibitor, TPV-2L
RePass et al. Molecular cloning, expression, and characterization of UDP N-acetyl-α-d-galactosamine: Polypeptide N-acetylgalactosaminyltransferase 4 from Cryptosporidium parvum
Moshitzky et al. Intracellular trafficking of FXYD1 (phospholemman) and FXYD7 proteins in Xenopus oocytes and mammalian cells
Huang et al. Characterization of the IRF2 proteins isolated from the deep-sea mussel Bathymodiolus platifrons and the shallow-water mussel Modiolus modiolus